Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.44 |
| ▸ | PPOX | P50336 | 1/20 | 0.44 |
| ▸ | AHR | P35869 | 2/20 | 0.43 |
| ▸ | CMA1 | P23946 | 1/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.36 |
| ▸ | HTR3B | O95264 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3817144 | 0.84 | CES1 (0.44) | CES1PPOXAHRCMA1TGM2 | |
| SCHEMBL4752422 | 0.84 | CES1 (0.44) | CES1PPOXAHRCMA1TGM2 | |
| SCHEMBL4753998 | 0.76 | CMA1 (0.43) | CES1AHRCMA1TGM2GRM2 | |
| SCHEMBL6219325 | 0.75 | CES1 (0.41) | CES1GRM2MAPTPDE7AGRIN2D | |
| SCHEMBL7202602 | 0.72 | PGR (0.40) | CHEK1 | |
| SCHEMBL20723 | 0.70 | MAPT (0.44) | AHRTP53MAPT | |
| SCHEMBL20505096 | 0.70 | MAPT (0.44) | AHRTP53MAPT | |
| SCHEMBL7367981 | 0.67 | GRIN2D (0.43) | CES1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3826696 | 0.67 | GRM5 (0.30) | — | |
| SCHEMBL4748741 | 0.67 | CYP3A4 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674789-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-03-09 | — | — | US | claimed |
| US-20090318424-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-24 | — | — | US | claimed |
| US-20090239846-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2009-09-24 | — | — | US | claimed |
| US-20090099157-A1 | TETRAHYDRO-PYRAZOLO-PYRIDINE THIOETHER MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | claimed |
| EP-2032142-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-03-11 | — | — | EP | claimed |
| WO-2008100621-A2 | TETRAHYDRO-PYRAZOLO-PYRIDINE THIOETHER MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | claimed |
| WO-2007147109-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | claimed |
| EP-1866311-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-19 | — | — | EP | claimed |
| US-20060235030-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | claimed |
| WO-2006104889-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-10-05 | — | — | WO | claimed |
| EP-2447266-B1 | Pyrimidopyridine compound used as a CSBP/RK/p38 modulator | GLAXO GROUP LTD (GB) | 2013-06-12 | — | — | EP | disclosed |
| US-8354416-B2 | 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-4-yl]-5-fluoro-4-methyl-N-(1-methylethyl)benzamide; treating CSBP/p38 kinase mediated diseases; cytokine suppressive anti-inflammatory drugs; mitogen-activated protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2013-01-15 | — | — | US | disclosed |
| EP-1868611-B1 | 8-PHENYL-7,8-DIHYDROPYRIDO[2,3-d]PYRIMIDIN-7-ONES | GLAXO GROUP LTD (GB) | 2012-11-14 | — | — | EP | disclosed |
| US-8207176-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| EP-2447266-A1 | Pyrimidopyridine compound used as a CSBP/RK/p38 modulator | GLAXO GROUP LIMITED (GB) | 2012-05-02 | — | — | EP | disclosed |
| WO-2007147104-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
| US-20060258687-A1 | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | GLAXO GROUP LIMITED (GB) | 2006-11-16 | — | — | US | disclosed |
| US-20060235029-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
| US-20060235030-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
| WO-2006104915-A2 | 8-PHENYL-7,8-DIHYDROPYRIDO[2,3-d]PYRIMIDIN-7-ONES AND THEIR USE AS PHARMACEUTICALS | GLAXO GROUP LIMITED (GB) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258687-A1 | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | CBR3, CBR1, CYP2S1 | CES1 3098/4885PPOX 48/4885AHR 647/4885 |
| US-20090239846-A1 | Novel Compounds | MAPKAPK2, MAPKAPK3, CDC42BPB | CES1 2189/4885PPOX 4628/4885AHR 4209/4885 |
| US-20060235030-A1 | Novel compounds | MAPKAPK2, MAPKAPK3, CDC42BPB | CES1 2189/4885PPOX 4628/4885AHR 4209/4885 |
| US-20090099157-A1 | TETRAHYDRO-PYRAZOLO-PYRIDINE THIOETHER MODULATORS OF CATHEPSIN S | CTSS, CTSE, CTSK | CES1 388/4885PPOX 124/4885AHR 1283/4885 |
| US-20060235029-A1 | Novel compounds | MAPKAPK2, CDC42BPB, MAPK8 | CES1 2834/4885PPOX 4397/4885AHR 4125/4885 |
| US-20090318424-A1 | NOVEL COMPOUNDS | MAPKAPK2, MAPKAPK3, CDC42BPB | CES1 2189/4885PPOX 4628/4885AHR 4209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.